Immunomodulatory Effects of Probiotic Bifidobacterium Bifidum with Tacrolimus and Sirolimus in Mouse Skin Graft Model
1Seoul National University College of Medicine, Seoul, Korea, Republic of, 2Inha University Hospital, Incheon, Korea, Republic of, 3Korea University Guro Hospital, Seoul, Korea, Republic of, 4Kyung Hee University Hospital, Seoul, Korea, Republic of, 5Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea, Republic of
Meeting: 2022 American Transplant Congress
Abstract number: 1293
Keywords: Mice, Skin transplantation, Synergism
Topic: Basic Science » Basic Science » 12 - Immunosuppression & Tolerance: Preclinical & Translational Studies
Session Information
Session Name: Immunosuppression & Tolerance: Preclinical & Translational Studies
Session Type: Poster Abstract
Date: Monday, June 6, 2022
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: Accumulating evidence suggests that gut microbiota actively crosstalks with the host immune system, and alterations of gut microbiota may exert immune regulatory effects. We aimed to identify probiotic strains capable of modulating the immune response in a mouse allogeneic skin graft model to evaluate its potential as a therapeutic adjunct in the transplantation field
*Methods: Tail skin of BALB/c mice was grafted to the back of C57BL6 mice. Recipient mice were treated with one of five probiotic strains (Lactobacillus lactis, Lactobacillus fermentum, Lactobacillus rhamnosus, Bifidobacterium bifidum, and Lactobacillus reuteri) alone or in conjunction with tacrolimus or sirolimus, and survival of the skin grafts was compared to the control groups with either no medication, tacrolimus without probiotics, or sirolimus without probiotics. The experiment was repeated for selected probiotic strains that showed immunomodulatory effects for quantitative assessment of cytokines using qRT-PCR.
*Results: Co-administration of B. bifidum with tacrolimus significantly improved skin allograft survival when compared to either the no medication group (mean 17 days vs. 11.7 days, p<0.001 by log-rank test) or to the tacrolimus only group (mean 17 days vs. 12.7 days, p<0.001 by log-rank test). B. bifidum also demonstrated synergistic survival improvement when administered with sirolimus (mean 15.6 days; p=0.019 and p =0.036 when compared to the control group and the sirolimus only group, respectively). Skin grafts from recipients treated with B. bifidum and tacrolimus or B. bifidum and sirolimus showed significantly increased expression of anti-inflammatory cytokine, IL-10. Expression of proinflammatory cytokine, IL-6 was also markedly inhibited in B. bifidum + sirolimus group.
*Conclusions: B. bifidum promoted allogeneic skin graft survival in mice synergistically with tacrolimus or sirolimus, possibly through induction of IL-10 production. Our study suggests that such a synergistic effect of B. bifidum may be applicable as an adjunct to conventional immunosuppressive therapy.
To cite this abstract in AMA style:
Han A, Chung C, Kim H, Ko H, Jo E, Min S, Kim S, Park H, Ha J. Immunomodulatory Effects of Probiotic Bifidobacterium Bifidum with Tacrolimus and Sirolimus in Mouse Skin Graft Model [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/immunomodulatory-effects-of-probiotic-bifidobacterium-bifidum-with-tacrolimus-and-sirolimus-in-mouse-skin-graft-model/. Accessed May 28, 2025.« Back to 2022 American Transplant Congress